AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 22, 2024
(Richard Jones/Science Photo Library/Getty Images) Scientists have discovered hundreds of genes that could potentially promote cancer, new research shows. Cancer is typically triggered by some kind of change to our genetic coding that interferes with a cell’s ability to manage its growth.
pharmaphorum
SEPTEMBER 22, 2024
FTC lawsuit accuses top three PBMs of using a perverse drug rebate system to artificially inflate the price of insulin products and their profits
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 22, 2024
The Association of Biotechnology Led Enterprises (ABLE) plays an intrinsic role as India’s bioeconomy propels innovation to leap towards the next phase of bio-manufacturing potential.
JAMA Internal Medicine
SEPTEMBER 22, 2024
This cohort study investigates the association between antihypertensive deprescribing and changes in cognitive function in nursing home residents.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA Law Blog
SEPTEMBER 22, 2024
By Steven J. Gonzalez & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — On August 22, 2024, FDA hosted a webinar to provide further guidance on the regulatory requirements it intends to apply to Laboratory Developed Test (LDT) developers in Stage 1 of the phaseout policy of the LDT Final Rule – during which FDA has said laboratories developing LDTs will need to comply with Medical Device Reporting (MDR) (21 CFR Part 803), Corrections and Removals (21 CFR Part 806), and Complaint
JAMA Internal Medicine
SEPTEMBER 22, 2024
This Viewpoint provides practicing clinicians who are considering choosing a new employer with guidance about questions relevant to evaluating governance, rewards systems, and culture.
Expert insights. Personalized for you.
244 
Let's personalize your content